GlassScriptPhysician profile
Gurmeet Singh
NPI 1518917152
$2,801.30
in general payments reported to CMS, 2019-2025
33 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $201 · 2021: $329 · 2022: $165 · 2023: $584 · 2024: $545 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Education: $98.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.40 |
| Education | $98.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $377.67 | 2021-2025 | |
| Harmony Biosciences LLC | $366.12 | 2020-2024 | Wakix |
| Pfizer INC. | $354.37 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $222.09 | 2024-2025 | Ingrezza |
| Abbvie INC. | $187.65 | 2021-2025 | |
| Amgen INC. | $146.21 | 2023-2025 | Uplizna, Aimovig |
| Biogen, INC. | $121.52 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $120.62 | 2019-2025 | Crexont, Rytary |
| Kyowa Kirin, INC. | $115.01 | 2020-2021 | |
| Allergan, INC. | $92.62 | 2019-2021 | |
| Abiomed | $74.96 | 2023 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $72.77 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $53.84 | 2021 | |
| Alexion Pharmaceuticals, INC. | $52.07 | 2019 | |
| Neurelis, INC. | $44.92 | 2024-2025 | Valtoco |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $41.96 | 2019-2022 | |
| Celgene Corporation | $35.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.71 | 2025 | Wainua |
| Agepha Pharma Fz LLC | $30.16 | 2025 | Lodoco |
| Axsome Therapeutics, INC. | $26.41 | 2025 | Symbravo |
| Emd Serono, INC. | $25.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.05 | 2019 | |
| Lilly USA, LLC | $23.58 | 2019 | |
| C2n Diagnostics, LLC | $19.94 | 2025 | Precivityad2 |
| Abbott Laboratories | $18.76 | 2023 | Amplatzer Talisman |
| Eisai INC. | $16.96 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.43 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.86 | 2019 | |
| Acorda Therapeutics, INC | $13.51 | 2019 | |
| Greenwich Biosciences, INC. | $12.72 | 2019 | |
| Zogenix INC. | $12.60 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurmeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.